Emma Jernberg
Overview
Explore the profile of Emma Jernberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ylitalo E, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S, et al.
Clin Epigenetics
. 2021 Jul;
13(1):133.
PMID: 34193246
Background: Patients with metastatic prostate cancer (PC) are treated with androgen deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal castration-resistant PC (CRPC) develops. A better...
2.
Thysell E, Vidman L, Ylitalo E, Jernberg E, Crnalic S, Iglesias-Gato D, et al.
Mol Oncol
. 2019 Jun;
13(8):1763-1777.
PMID: 31162796
Bone metastasis is the lethal end-stage of prostate cancer (PC), but the biology of bone metastases is poorly understood. The overall aim of this study was therefore to explore molecular...
3.
Nordstrand A, Ylitalo E, Thysell E, Jernberg E, Crnalic S, Widmark A, et al.
Int J Mol Sci
. 2018 Apr;
19(4).
PMID: 29670000
Advanced prostate cancer frequently metastasizes to bone and induces a mixed osteoblastic/osteolytic bone response. Standard treatment for metastatic prostate cancer is androgen-deprivation therapy (ADT) that also affects bone biology. Treatment...
4.
Thysell E, Ylitalo E, Jernberg E, Bergh A, Wikstrom P
Cancer Res
. 2017 Dec;
77(24):7131-7132.
PMID: 29212852
No abstract available.
5.
Jernberg E, Bergh A, Wikstrom P
Endocr Connect
. 2017 Oct;
6(8):R146-R161.
PMID: 29030409
Prostate cancer (PC) remains a leading cause of cancer-related deaths among men worldwide, despite continuously improved treatment strategies. Patients with metastatic disease are treated by androgen deprivation therapy (ADT) that...
6.
Thysell E, Ylitalo E, Jernberg E, Bergh A, Wikstrom P
Eur Urol
. 2017 Jun;
72(4):e104-e105.
PMID: 28642023
No abstract available.
7.
Djusberg E, Jernberg E, Thysell E, Golovleva I, Lundberg P, Crnalic S, et al.
Prostate
. 2017 Feb;
77(6):625-638.
PMID: 28144969
Background: The relation between androgen receptor (AR) gene amplification and other mechanisms behind castration-resistant prostate cancer (CRPC), such as expression of constitutively active AR variants and steroid-converting enzymes has been...
8.
Ylitalo E, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, et al.
Eur Urol
. 2016 Aug;
71(5):776-787.
PMID: 27497761
Background: Novel therapies for men with castration-resistant prostate cancer (CRPC) are needed, particularly for cancers not driven by androgen receptor (AR) activation. Objectives: To identify molecular subgroups of PC bone...
9.
Bergstrom S, Nilsson M, Adamo H, Thysell E, Jernberg E, Stattin P, et al.
PLoS One
. 2016 Jun;
11(6):e0157280.
PMID: 27280718
Aggressive tumors induce tumor-supporting changes in the benign parts of the prostate. One factor that has increased expression outside prostate tumors is hemoxygenase-1 (HO-1). To investigate HO-1 expression in more...
10.
Nilsson M, Hagglof C, Hammarsten P, Thysell E, Stattin P, Egevad L, et al.
PLoS One
. 2015 Oct;
10(10):e0140985.
PMID: 26501565
Lysyl oxidase (LOX) has been shown to both promote and suppress tumor progression, but its role in prostate cancer is largely unknown. LOX immunoreactivity was scored in prostate tumor epithelium,...